The entecavir market size has grown steadily in recent years. It will grow from $0.74 billion in 2025 to $0.77 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to high global hepatitis b prevalence, clinical success of nucleoside analogs, expansion of antiviral treatment guidelines, improved hepatitis b diagnosis rates, increasing liver disease burden.
The entecavir market size is expected to see steady growth in the next few years. It will grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growth in chronic hepatitis b patient pool, rising access to antiviral therapies in emerging markets, increasing adoption of long-term viral suppression strategies, expansion of public health hepatitis programs, growing demand for affordable generics. Major trends in the forecast period include rising long-term antiviral therapy adoption, increasing focus on chronic hepatitis b management, growing demand for oral antiviral medications, expansion of generic entecavir availability, increased monitoring of viral load suppression.
The rising prevalence of hepatitis B is anticipated to drive the growth of the entecavir market in the coming years. Hepatitis B is a viral infection that impacts the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can progress to chronic liver disease or liver cancer if not treated. The surge in hepatitis B cases is linked to factors including unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and inadequate vaccination coverage in certain areas. Entecavir treats hepatitis B by blocking the replication of hepatitis B virus (HBV) DNA, lowering viral load and preventing liver damage. For example, in August 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, non-Hispanic Asian/Pacific Islander individuals had a rate of newly reported chronic hepatitis B cases nearly 10 times higher than that of non-Hispanic White individuals. Hence, the growing prevalence of hepatitis B is fueling the expansion of the entecavir market.
The increasing healthcare expenditure is anticipated to drive the growth of the entecavir market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical goods and services aimed at maintaining and improving population health. This expenditure is rising due to an aging population that requires more frequent medical care and long-term health services. Higher healthcare spending supports entecavir adoption because greater national investment in antiviral treatments and chronic disease management enables wider access to hepatitis B therapies. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported that between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. Thus, the increasing healthcare expenditure is expected to drive the growth of the entecavir market.
Major companies in the entecavir sector are focusing on developing innovative drugs through clinical trials to improve efficacy and treatment outcomes for patients with chronic hepatitis B, potentially lowering resistance and enhancing long-term viral suppression. Clinical trials are research studies conducted to assess the safety, effectiveness, and possible side effects of new treatments, drugs, or therapies in human participants. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology firm, initiated a phase 2 clinical trial for ALG-000184 to treat hepatitis B. ALG-000184 is a therapy classified as a capsid assembly modulator, which functions by interfering with the formation of the capsid, the protective shell surrounding the virus’s genetic material. The fourth phase of the study is currently evaluating the long-term effects of ALG-000184 (300 mg), either as a standalone therapy or in combination with the approved antiviral entecavir, in patients with chronic hepatitis B. The combination of ALG-000184 and entecavir led to more substantial reductions in viral load compared to entecavir alone, with ALG-000184 showing similar efficacy whether used alongside entecavir or not. Viral suppression remained consistent throughout the study in both HBeAg-positive and HBeAg-negative patients.
Major companies operating in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc., HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.
Asia-Pacific was the largest region in the entecavir market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the entecavir market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the entecavir market by increasing the cost of imported active pharmaceutical ingredients and finished antiviral products used in hepatitis treatment. These impacts are most notable in tablet manufacturing and hospital pharmacy procurement, where cost efficiency and supply continuity are critical. Regions such as Asia Pacific and North America have experienced higher input costs due to reliance on cross border antiviral sourcing. Rising tariff related expenses have influenced pricing strategies, procurement planning, and inventory management for antiviral therapies. However, tariffs have also encouraged localized API production, expanded domestic antiviral manufacturing capacity, and strengthened long term supply chain resilience.
The entecavir market research report is one of a series of new reports that provides entecavir market statistics, including entecavir industry global market size, regional shares, competitors with a entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Entecavir is an antiviral medication used to treat chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which decreases the viral load. This action helps minimize the risk of serious liver damage and complications, including cirrhosis and liver cancer.
The primary forms of entecavir are tablets and oral solution. Entecavir tablets are administered orally and are indicated for the management of chronic hepatitis B (CHB) infection. They are utilized for multiple purposes, including hepatitis B therapy, liver transplantation, and other applications. These are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The entecavir market size is expected to see steady growth in the next few years. It will grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growth in chronic hepatitis b patient pool, rising access to antiviral therapies in emerging markets, increasing adoption of long-term viral suppression strategies, expansion of public health hepatitis programs, growing demand for affordable generics. Major trends in the forecast period include rising long-term antiviral therapy adoption, increasing focus on chronic hepatitis b management, growing demand for oral antiviral medications, expansion of generic entecavir availability, increased monitoring of viral load suppression.
The rising prevalence of hepatitis B is anticipated to drive the growth of the entecavir market in the coming years. Hepatitis B is a viral infection that impacts the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can progress to chronic liver disease or liver cancer if not treated. The surge in hepatitis B cases is linked to factors including unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and inadequate vaccination coverage in certain areas. Entecavir treats hepatitis B by blocking the replication of hepatitis B virus (HBV) DNA, lowering viral load and preventing liver damage. For example, in August 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, non-Hispanic Asian/Pacific Islander individuals had a rate of newly reported chronic hepatitis B cases nearly 10 times higher than that of non-Hispanic White individuals. Hence, the growing prevalence of hepatitis B is fueling the expansion of the entecavir market.
The increasing healthcare expenditure is anticipated to drive the growth of the entecavir market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical goods and services aimed at maintaining and improving population health. This expenditure is rising due to an aging population that requires more frequent medical care and long-term health services. Higher healthcare spending supports entecavir adoption because greater national investment in antiviral treatments and chronic disease management enables wider access to hepatitis B therapies. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported that between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. Thus, the increasing healthcare expenditure is expected to drive the growth of the entecavir market.
Major companies in the entecavir sector are focusing on developing innovative drugs through clinical trials to improve efficacy and treatment outcomes for patients with chronic hepatitis B, potentially lowering resistance and enhancing long-term viral suppression. Clinical trials are research studies conducted to assess the safety, effectiveness, and possible side effects of new treatments, drugs, or therapies in human participants. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology firm, initiated a phase 2 clinical trial for ALG-000184 to treat hepatitis B. ALG-000184 is a therapy classified as a capsid assembly modulator, which functions by interfering with the formation of the capsid, the protective shell surrounding the virus’s genetic material. The fourth phase of the study is currently evaluating the long-term effects of ALG-000184 (300 mg), either as a standalone therapy or in combination with the approved antiviral entecavir, in patients with chronic hepatitis B. The combination of ALG-000184 and entecavir led to more substantial reductions in viral load compared to entecavir alone, with ALG-000184 showing similar efficacy whether used alongside entecavir or not. Viral suppression remained consistent throughout the study in both HBeAg-positive and HBeAg-negative patients.
Major companies operating in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc., HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.
Asia-Pacific was the largest region in the entecavir market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the entecavir market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the entecavir market by increasing the cost of imported active pharmaceutical ingredients and finished antiviral products used in hepatitis treatment. These impacts are most notable in tablet manufacturing and hospital pharmacy procurement, where cost efficiency and supply continuity are critical. Regions such as Asia Pacific and North America have experienced higher input costs due to reliance on cross border antiviral sourcing. Rising tariff related expenses have influenced pricing strategies, procurement planning, and inventory management for antiviral therapies. However, tariffs have also encouraged localized API production, expanded domestic antiviral manufacturing capacity, and strengthened long term supply chain resilience.
The entecavir market research report is one of a series of new reports that provides entecavir market statistics, including entecavir industry global market size, regional shares, competitors with a entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Entecavir is an antiviral medication used to treat chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which decreases the viral load. This action helps minimize the risk of serious liver damage and complications, including cirrhosis and liver cancer.
The primary forms of entecavir are tablets and oral solution. Entecavir tablets are administered orally and are indicated for the management of chronic hepatitis B (CHB) infection. They are utilized for multiple purposes, including hepatitis B therapy, liver transplantation, and other applications. These are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Entecavir Market Characteristics
3. Entecavir Market Supply Chain Analysis
4. Global Entecavir Market Trends and Strategies
5. Entecavir Market Analysis of End Use Industries
7. Global Entecavir Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Entecavir Total Addressable Market (TAM) Analysis for the Market
9. Entecavir Market Segmentation
10. Entecavir Market Regional and Country Analysis
11. Asia-Pacific Entecavir Market
12. China Entecavir Market
13. India Entecavir Market
14. Japan Entecavir Market
15. Australia Entecavir Market
16. Indonesia Entecavir Market
17. South Korea Entecavir Market
18. Taiwan Entecavir Market
19. South East Asia Entecavir Market
20. Western Europe Entecavir Market
21. UK Entecavir Market
22. Germany Entecavir Market
23. France Entecavir Market
24. Italy Entecavir Market
25. Spain Entecavir Market
26. Eastern Europe Entecavir Market
27. Russia Entecavir Market
28. North America Entecavir Market
29. USA Entecavir Market
30. Canada Entecavir Market
31. South America Entecavir Market
32. Brazil Entecavir Market
33. Middle East Entecavir Market
34. Africa Entecavir Market
36. Entecavir Market Competitive Landscape and Company Profiles
37. Entecavir Market Other Major and Innovative Companies
40. Entecavir Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Entecavir Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses entecavir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for entecavir? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The entecavir market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Tablets; Oral Solution2) By Application: Hepatitis B Treatment; Liver Transplantation; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Tablets: Standard Dose Tablets; High Dose Tablets2) By Oral Solution: Ready-to-Use Liquid Solution; Powder For Oral Solution
Companies Mentioned: Bristol-Myers Squibb Company; GSK plc; Teva Pharmaceutical Industries Ltd.; Qingfeng Pharmaceutical Group; Aurobindo Pharma Ltd.; ScinoPharm Taiwan Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Inc.; Zhejiang Huahai Pharmaceuticals Co. Ltd.; Qianjin Group; Genix Pharma Ltd.; Dawnrays Pharmaceutical Holidings Ltd.; Zhejiang Ausun Pharmaceutical Co. Ltd.; Hunan Warrant Chiral Pharmaceutical Co. Ltd.; Camber Pharmaceuticals Inc.; Century Pharmaceuticals Ltd.; Aligos Therapeutics Inc. ; HRV Global Life Sceince; Solco Healthcare LLC; Accela ChemBio Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Entecavir market report include:- Bristol-Myers Squibb Company
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- Qingfeng Pharmaceutical Group
- Aurobindo Pharma Ltd.
- ScinoPharm Taiwan Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Inc.
- Zhejiang Huahai Pharmaceuticals Co. Ltd.
- Qianjin Group
- Genix Pharma Ltd.
- Dawnrays Pharmaceutical Holidings Ltd.
- Zhejiang Ausun Pharmaceutical Co. Ltd.
- Hunan Warrant Chiral Pharmaceutical Co. Ltd.
- Camber Pharmaceuticals Inc.
- Century Pharmaceuticals Ltd.
- Aligos Therapeutics Inc.
- HRV Global Life Sceince
- Solco Healthcare LLC
- Accela ChemBio Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.77 Billion |
| Forecasted Market Value ( USD | $ 0.9 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
